Endometrial Cancer

Latest News

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.
Frontline Advanced Endometrial Cancer Therapy Confers High Economic Burden

November 27th 2023

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.

Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer
Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer

November 26th 2023

Investigators report a trend in overall survival improvement among patients with advanced/recurrent endometrial cancer treated with atezolizumab and chemotherapy.
Atezolizumab/Chemo Provides PFS Benefit in Advanced Endometrial Cancer

November 21st 2023

The progression-free survival benefit of dostarlimab and chemotherapy extends to those with mismatch repair deficient or microsatellite instability–high advanced endometrial cancer.
Dostarlimab Combo Significantly Improves PFS in Advanced Endometrial Cancer

November 16th 2023

Investigators report that loss of MMR mechanism is not predictive of response to chemotherapy or pembrolizumab in patients with stage III or IVA, stage IVB, or recurrent endometrial cancer.
Pembrolizumab/Chemo May Be New Standard in dMMR/pMMR Endometrial Cancer

November 14th 2023

More News